{
    "clinical_study": {
        "@rank": "3108", 
        "arm_group": {
            "arm_group_label": "Vaginal Bromocriptine", 
            "arm_group_type": "Experimental", 
            "description": "Patients will receive 2.5 mg of vaginal bromocriptine tablet twice a day for the intervention. This will be administered for 6 months."
        }, 
        "brief_summary": {
            "textblock": "Adenomyosis is a rare non-malignant disease of the uterus that causes significant symptoms\n      including heavy menstrual bleeding and pelvic pain.  The only widely accepted treatment for\n      adenomyosis is hysterectomy. The investigators will use a dopamine agonist, bromocriptine,\n      as a therapy based on animal models of the disease and our prior clinical research to\n      observe any objective improvement in the extent of the disease using Magnetic Resonance\n      Imaging (MRI)and standard measurements for other gynecologic diseases to measure\n      symptomatology."
        }, 
        "brief_title": "Vaginal Bromocriptine for Treatment of Adenomyosis", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Adenomyosis", 
        "condition_browse": {
            "mesh_term": "Endometriosis"
        }, 
        "detailed_description": {
            "textblock": "Women with adenomyosis proven with MRI will be considered for the intervention with\n      bromocriptine. They will be reassessed at 1, 6 and 9 months. Patients will get a stipend for\n      each visit they complete. The study will end for the enrolled subject at 9th month follow-up"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Women able to give informed consent and willing and able to attend all study visits\n\n          2. Premenopausal women at least 25 years of age\n\n          3. No evidence of High Grade SIL by pap smears or HPV testing within institutional\n             guidelines\n\n          4. MRI or ultrasound imaging consistent or highly suggestive of adenomyosis\n\n          5. Use of barrier contraception, sterilization or sexual abstinence\n\n        Exclusion Criteria:\n\n          1. Women actively trying for pregnancy, currently pregnant, less than six months\n             postpartum or breastfeeding\n\n          2. Uterine size > 20 weeks\n\n          3. Active pelvic infection or current use of intrauterine contraceptive device\n\n          4. Current use of GnRH agonists or antagonists, or contraceptive steroids\n\n          5. MRI suggestive of malignant disease of uterus, ovary, or cervix\n\n          6. Hypersensitivity to bromocriptine or ergot alkaloids\n\n          7. History of gastrointestinal ulcers\n\n          8. History of syncope, syncopal migraine or seizure\n\n          9. Uncontrolled hypertension\n\n         10. History of myocardial infarction, uncontrolled hypertension, heart valve disorder or\n             cerebrovascular accident\n\n         11. History of diabetes mellitus except gestational diabetes\n\n         12. History of Parkinson's Disease\n\n         13. History of psychosis\n\n         14. History of pleural or pericardial effusion\n\n         15. History of pulmonary fibrosis or thickening of the pleura\n\n         16. History of lactose intolerance\n\n         17. History of Reynaud's Disease\n\n         18. Use of antidepressants\n\n         19. Use of opioid pain medications"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "25 Years"
        }, 
        "enrollment": {
            "#text": "33", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01821001", 
            "org_study_id": "11-007353"
        }, 
        "intervention": {
            "arm_group_label": "Vaginal Bromocriptine", 
            "description": "Patients will receive 2.5 mg of vaginal bromocriptine tablet twice a day for the intervention. This will be administered for 6 months.", 
            "intervention_name": "Vaginal Bromocriptine", 
            "intervention_type": "Drug", 
            "other_name": [
                "Cycloset", 
                "Parlodel"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Bromocriptine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Adenomyosis", 
            "Dysmenorrhea", 
            "Abnormal Uterine bleeding", 
            "Heavy Menstrual Bleeding", 
            "Menorrhagia"
        ], 
        "lastchanged_date": "May 29, 2014", 
        "location": {
            "contact": {
                "email": "allen.kristi1@mayo.edu", 
                "last_name": "Kristi L Allen, RN", 
                "phone": "507-293-3446"
            }, 
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55905"
                }, 
                "name": "Mayo Clinic in Rochester"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Vaginal Bromocriptine for the Treatment of Adenomyosis", 
        "overall_contact": {
            "email": "allen.kristi1@mayo.edu", 
            "last_name": "Kristi L Allen, RN", 
            "phone": "507-293-3446"
        }, 
        "overall_contact_backup": {
            "email": "khan.zaraq@mayo.edu", 
            "last_name": "Zaraq Khan, MBBS"
        }, 
        "overall_official": [
            {
                "affiliation": "Mayo Clinic", 
                "last_name": "Elizabeth Stewart, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Mayo Clinic", 
                "last_name": "Zaraq Khan, MBBS", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "All patients will get a baseline imaging of the uterus with MRI and a brief procedure, similar to a pap smear, to obtain tissue from the uterus and also a blood draw. Patients will then receive vaginal bromocriptine twice daily and will be reassessed at 6 months with an MRI to see objective improvement in the extent of the disease.  This 6 month visit is the only one that would require an in person visit to the research site (Mayo Clinic in this case)", 
            "measure": "Objective improvement of adenomyosis", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01821001"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Elizabeth  A. Stewart", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Patients will fill out questionnaires at 1, 3, 6 and 9 months. These questionnaires are validated for study of gynecologic diseases and assess the severity of symptoms in patients.", 
            "measure": "Scores from questionnaires that assess the severity of symptoms from adenomyosis", 
            "safety_issue": "No", 
            "time_frame": "9 months"
        }, 
        "source": "Mayo Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}